{"ModuleTitle": "Company Description", "CompanyName": "Insmed, Inc.", "Symbol": "INSM", "Address": "700 US HIGHWAY 202/206, BRIDGEWATER, New Jersey, 08807, United States of America", "Phone": "908-977-9900", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a global biopharmaceutical company on a mission to transform the lives of\r\npatients with serious and rare diseases. Our first commercial product, ARIKAYCE,\r\nreceived accelerated approval in the US in September 2018 for the treatment of\r\nMycobacterium avium complex (MAC) lung disease as part of a combination\r\nantibacterial drug regimen for adult patients with limited or no alternative\r\ntreatment options in a refractory setting, as defined by patients who do not\r\nachieve negative sputum cultures after a minimum of six consecutive months of a\r\nmultidrug background regimen therapy. Nontuberculous mycobacterial (NTM) lung\r\ndisease caused by MAC (which we refer to as MAC lung disease) is a rare and\r\noften chronic infection that can cause irreversible lung damage and can be\r\nfatal. Our clinical-stage pipeline includes INS1007 and INS1009.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f25%2f0001104506-20-000007.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Martina Flammer", "title": "Chief Medical Officer"}, {"name": "Roger Adsett", "title": "Chief Operating Officer"}, {"name": "Sara M. Bonstein", "title": "Chief Financial Officer"}, {"name": "Walter R. Perkins", "title": "Chief Technology Officer"}, {"name": "William H. Lewis", "title": "Chairman, President & Chief Executive Officer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}